{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:48:27Z","timestamp":1782254907411,"version":"3.54.5"},"reference-count":41,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T00:00:00Z","timestamp":1268870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic>\u2002<jats:bold>31<\/jats:bold>, 1296\u20131309<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> In the randomized, double\u2010blind, placebo\u2010controlled CHARM trial, adalimumab was more effective than placebo in maintaining clinical remission for patients with moderate\u2010to\u2010severe Crohn\u2019s disease (CD) through 56\u2003weeks.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To substantiate the long\u2010term safety and clinical benefits of adalimumab through 2\u2003years of therapy in CHARM and its open\u2010label extension (ADHERE).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Patients entering ADHERE on blinded therapy received adalimumab 40\u2003mg every other week (eow). Patients who had already moved to open\u2010label adalimumab eow or weekly in CHARM continued their regimens. Data were analysed by originally randomized treatment group at CHARM baseline (adalimumab 40\u2003mg eow, adalimumab 40\u2003mg weekly, or placebo), regardless of whether patients entered ADHERE or received open\u2010label adalimumab (eow or weekly).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> After up to 2\u2003years of therapy, 37.6%, 41.9% and 49.8% of patients originally randomized to placebo, adalimumab eow and adalimumab weekly, respectively, were in clinical remission. All groups experienced sustained improvements on the Inflammatory Bowel Disease Questionnaire. Decreasing hazard rates for both all\u2010cause and CD\u2010related hospitalizations were observed over time. Over a 2\u2010year period, the rates of serious adverse events and malignancies (33.3 and 1.1 events\/100\u2010patient\u2010years respectively) were similar to those observed during the overall adalimumab CD clinical development programme.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Adalimumab demonstrated sustained maintenance of clinical remission, improvements in quality of life and reductions in hospitalization during long\u2010term treatment for CD, with no new safety concerns identified.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2010.04304.x","type":"journal-article","created":{"date-parts":[[2010,5,24]],"date-time":"2010-05-24T04:04:05Z","timestamp":1274673845000},"page":"1296-1309","source":"Crossref","is-referenced-by-count":86,"title":["Adalimumab sustains clinical remission and overall clinical benefit after 2\u2003years of therapy for Crohn\u2019s disease"],"prefix":"10.1111","volume":"31","author":[{"given":"R.","family":"PANACCIONE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010F.","family":"COLOMBEL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. J.","family":"SANDBORN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"RUTGEERTS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R.","family":"D\u2019HAENS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"ROBINSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"CHAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"MULANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. F.","family":"POLLACK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.6.777"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60304-9"},{"issue":"1","key":"e_1_2_7_11_2","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.14309\/00000434-200809001-01117","article-title":"SONIC: A randomized, double\u2010blind, controlled trial comparing infliximab and infliximab plus azathioprine in patients with Crohn\u2019s disease na\u00efve to immunomodulators and biologic therapy [abstract 1117]","volume":"103","author":"Sandborn WJ","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1572-0241.2003.04010.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.069"},{"key":"e_1_2_7_14_2","first-page":"20","article-title":"Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn\u2019s disease","volume":"21","author":"Wu EQ","year":"2008","journal-title":"Manag Care Interface"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32832a8d71"},{"key":"e_1_2_7_16_2","first-page":"319","article-title":"The costs of Crohn\u2019s disease in the United States and other Western countries: a systematic review","volume":"24","author":"Yu AP","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.159251"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.59"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02175.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90585-1"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20956"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.006"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.168"},{"issue":"2","key":"e_1_2_7_25_2","article-title":"Early Crohn\u2019s disease shows high levels of remission to therapy with adalimumab","volume":"4","author":"Schreiber S","year":"2007","journal-title":"Gastroenterology"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21034"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20205"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9969-z"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(06)73161-X"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20329"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.048"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.155812"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102103"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04033.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.2165\/11312710-000000000-00000"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(08)61619-4"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(09)60791-5"},{"key":"e_1_2_7_38_2","first-page":"173","article-title":"Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn\u2019s disease in the United States","volume":"15","author":"Pan X","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00335.x"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20177"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(09)60659-4"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.004"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04304.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04304.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2010.04304.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T14:08:19Z","timestamp":1694786899000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04304.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,20]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1365-2036.2010.04304.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04304.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,20]]}}}